Hemophilia A News and Research

RSS

Experimental drug therapy could open new window for treatment of deadly stroke

A new type of drug therapy that is currently being tested in Canada could significantly reduce the death rate caused by the deadliest form of stroke. According to the Canadian Heart and Stroke Foundation, new developments in stroke research make it more important than ever that Canadians recognize and react to the warning signs of stroke.

9 Jun 2005

Over 3,000 lives lost because of blood bungle by Canadian Red Cross

The Canadian Red Cross has pleaded guilty to distributing contaminated blood supplies. Since getting the tainted blood in the 1980s thousands of Canadians with HIV and hepatitis C were infected and more than 3,000 people have died.

31 May 2005

Vaccine prevents deadly pneumonia in African children

Global health leaders today presented new research showing that vaccinating infants against Streptococcus pneumoniae -- a bacterium that causes deadly pneumonia, meningitis and sepsis -- could substantially reduce death and serious illness among children in the developing world. If used widely, a pneumococcal conjugate vaccine could prevent hundreds of thousands of child deaths each year.

28 Mar 2005

Discovery may have implications for the treatment of hemophilia A and B

University of North Carolina at Chapel Hill researchers have made a discovery that may have implications for the treatment of liver-based genetic defects such as hemophilia A and B in humans.

15 Feb 2005

Researchers grow mouth lining into pieces of bio-bandage

University of Michigan researchers are testing a new procedure in which they can take a tiny piece of a person's mouth lining, grow it into a dollar-bill sized piece of tissue and graft that expanded piece into the donor's mouth to heal a wound.

5 Oct 2004

Wyeth gets approval for needle-less syringe for the treatment of hemophilia

Wyeth Pharmaceuticals has announced that it has received approval from the U.S. Food and Drug Administration (FDA) for the ReFacto Antihemophilic Factor (Recombinant) R2 Kit, the first needle-less reconstitution device with a prefilled diluent syringe for hemophilia.

14 Sep 2004

Mitochondrial genes cause nuclear mischief

While the nucleus of a cell may be its command headquarters, mitochondria are equally vital—they are the power plants of the cell, and without them all cellular activity would quickly and irrevocably come to a halt.

7 Sep 2004

Streptococcal bacteria disrupts blood clotting to infect humans

University of Michigan researchers have captured a glimpse of the endless arms race between infectious agents and the human immune system in a bacterium that uses a mimic of a human blood-clotting enzyme to advance its infection.

27 Aug 2004

Smart gene therapy might effectively prevent the organ damage commonly suffered by heart attack victims

Early intervention with a novel kind of "smart gene therapy" might effectively prevent the organ damage commonly suffered by heart attack victims, suggests a new animal study by researchers at Brigham and Women's Hospital in Boston and Duke University Medical Center.

2 Aug 2004

2,332 dengue fever cases reported in Philippines this year

The Philippines Department of Health (DOH) today reported that a total of 2,332 dengue cases has been admitted to sentinel hospitals nationwide from January 1 to May 15 this year. There were sixteen deaths recorded.

16 Jun 2004

FDA finalizes new rule on donor eligibility for human tissues and cells

FDA today published a final rule establishing donor eligibility criteria for donors of human cells, tissues, and cellular and tissue-based products (HCT/Ps) to help prevent the transmission of communicable disease when these products are transplanted.

20 May 2004

Study Looks at Risk Factors for Range-of-Motion Limitations In Young Males with Hemophilia

A paper in the April issue of Blood detailed research on the prevalence and risk factors joint range of motion (ROM) limitation among young males with hemophilia.

4 Apr 2004